Diagnostic value of soluble biomarkers for parapneumonic pleural effusion

被引:7
作者
Cao, Xi-Shan [1 ]
Zheng, Wen-Qi [1 ,2 ]
Hu, Zhi-De [1 ,2 ]
机构
[1] Inner Mongolia Med Univ, Dept Lab Med, Affiliated Hosp, Hohhot, Peoples R China
[2] Inner Mongolia Med Univ, Dept Lab Med, Affiliated Hosp, Hohhot, Peoples R China
关键词
Parapneumonic pleural effusion; circulating biomarkers; diagnosis; C-REACTIVE PROTEIN; TUMOR-NECROSIS-FACTOR; ENDOTHELIAL GROWTH-FACTOR; CELL-FREE DNA; DIFFERENTIAL-DIAGNOSIS; TISSUE INHIBITORS; MYELOID CELLS-1; FACTOR-ALPHA; PROINFLAMMATORY CYTOKINES; MATRIX METALLOPROTEINASES;
D O I
10.1080/10408363.2022.2158779
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Parapneumonic pleural effusion (PPE) is a common complication in patients with pneumonia. Timely and accurate diagnosis of PPE is of great value for its management. Measurement of biomarkers in circulating and pleural fluid have the advantages of easy accessibility, short turn-around time, objectiveness and low cost and thus have utility for PPE diagnosis and stratification. To date, many biomarkers have been reported to be of value for the management of PPE. Here, we review the values of pleural fluid and circulating biomarkers for the diagnosis and stratification PPE. The biomarkers discussed are C-reactive protein, procalcitonin, presepsin, soluble triggering receptor expressed on myeloid cells 1, lipopolysaccharide-binding protein, inflammatory markers, serum amyloid A, soluble urokinase plasminogen activator receptor, matrix metalloproteinases, pentraxin-3 and cell-free DNA. We found that none of the available biomarkers has adequate performance for diagnosing and stratifying PPE. Therefore, further work is needed to identify and validate novel biomarkers, and their combinations, for the management of PPE.
引用
收藏
页码:233 / 247
页数:15
相关论文
共 170 条
[1]   Parapneumonic Effusion and Empyema [J].
Addala, Dinesh N. ;
Bedawi, Eihab O. ;
Rahman, Najib M. .
CLINICS IN CHEST MEDICINE, 2021, 42 (04) :637-647
[2]   The differential diagnostic values of cytokine levels in pleural effusions [J].
Akarsu, S ;
Kurt, ANC ;
Dogan, Y ;
Yilmaz, E ;
Godekmerdan, A ;
Aygun, AD .
MEDIATORS OF INFLAMMATION, 2005, (01) :2-8
[3]   Pathogen recognition and innate immunity [J].
Akira, S ;
Uematsu, S ;
Takeuchi, O .
CELL, 2006, 124 (04) :783-801
[4]   Elevated C-reactive protein in the diagnosis, prognosis, and cause of cancer [J].
Allin, Kristine H. ;
Nordestgaard, Borge G. .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2011, 48 (04) :155-170
[5]   Procalcitonin: Between evidence and critical issues [J].
Aloisio, Elena ;
Dolci, Alberto ;
Panteghini, Mauro .
CLINICA CHIMICA ACTA, 2019, 496 :7-12
[6]   Pleural Fluid suPAR Levels Predict the Need for Invasive Management in Parapneumonic Effusions [J].
Arnold, David T. ;
Hamilton, Fergus W. ;
Elvers, Karen T. ;
Frankland, Stuart W. ;
Zahan-Evans, Natalie ;
Patole, Sonia ;
Medford, Andrew ;
Bhatnagar, Rahul ;
Maskell, Nicholas A. .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201 (12) :1545-1553
[7]   Elevated pleural fluid levels of defensins in patients with empyema [J].
Ashitani, J ;
Mukae, H ;
Nakazato, M ;
Taniguchi, H ;
Ogawa, K ;
Kohno, S ;
Matsukura, S .
CHEST, 1998, 113 (03) :788-794
[8]   Thoracentesis outcomes: a 12-year experience [J].
Ault, Mark J. ;
Rosen, Bradley T. ;
Scher, Jordan ;
Feinglass, Joe ;
Barsuk, Jeffrey H. .
THORAX, 2015, 70 (02) :127-132
[9]   INTERLEUKIN-8, A CHEMOTACTIC AND INFLAMMATORY CYTOKINE [J].
BAGGIOLINI, M ;
CLARKLEWIS, I .
FEBS LETTERS, 1992, 307 (01) :97-101
[10]   SuPAR in pleural fluid may function as a biological marker for infection in critically ill patients with pleural effusions [J].
Bakker, Olga G. M. ;
Hemmes, Sabrine N. T. ;
Backes, Yara ;
Determann, Rogier M. ;
Schultz, Marcus J. .
JOURNAL OF INFECTION, 2014, 68 (06) :607-609